Preview Mode Links will not work in preview mode

This Week in Cardiology

Feb 24, 2023

Reporting on potential fraud in medicine, AF, stroke, a possible new cholesterol-lowering drug, and the tone of debate in medical science are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

I. Potential Fraud in Medicine

Inside the Big Business of Clogged Arteries

II. AF Screening and Stroke

STROKE AF at 3 Years: High AF Rate After Atherosclerotic Stroke

Severity and Etiology of Incident Stroke in Patients Screened for Atrial Fibrillation vs Usual Care and the Impact of Prior Stroke

III. Bempedoic Acid

New Studies Give Bempedoic Acid a Bump as Lipid-Lowering Agent

- Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance

- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

- Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease

- N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects

- Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment

IV. The Technique of Critical Appraisal

Why Evidence-Based Medicine Enthusiasts Could Use a Lesson in Persuasion

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD

Questions or feedback, please contact